Lyra Therapeutics Inc LYRA

NAS: LYRA | ISIN: US55234L1052   31/05/2024
0,328 USD (-1,09%)
(-1,09%)   31/05/2024

26 september 2023 · Thinking about buying stock in Gaucho Group Holdings, Lyra Therapeutics, Biophytis, Archer Aviation, or Femasys? · Persbericht

13 september 2022 · Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

13 september 2022 · Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study · Persbericht

10 september 2022 · LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting · Persbericht

8 september 2022 · Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients · Persbericht

6 september 2022 · Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022 · Persbericht

29 augustus 2022 · Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting · Persbericht

9 augustus 2022 · Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update · Persbericht

5 juli 2022 · Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022 · Persbericht

5 juli 2022 · Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer · Persbericht

17 juni 2022 · Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

26 mei 2022 · Lyra Therapeutics to Present at Upcoming Investor Conferences · Persbericht

10 mei 2022 · Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update · Persbericht

5 mei 2022 · Lyra Therapeutics to Present at Upcoming Investor Conferences · Persbericht

29 april 2022 · Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022 · Persbericht

25 april 2022 · Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients · Persbericht

21 april 2022 · Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022 · Persbericht

13 april 2022 · Lyra Therapeutics Announces Closing of $100.5 Million Private Placement · Persbericht

8 april 2022 · Lyra Therapeutics Announces $100.5 Million Private Placement · Persbericht

9 maart 2022 · Lyra Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update · Persbericht

Mijn selecties